United Therapeutics Corporation (UTHR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
United Therapeutics Corporation stock (UTHR) is currently trading at $541.60. United Therapeutics Corporation PE ratio is 19.43. United Therapeutics Corporation PS ratio (Price-to-Sales) is 7.46. Analyst consensus price target for UTHR is $593.92. WallStSmart rates UTHR as Moderate Buy.
- UTHR PE ratio analysis and historical PE chart
- UTHR PS ratio (Price-to-Sales) history and trend
- UTHR intrinsic value — DCF, Graham Number, EPV models
- UTHR stock price prediction 2025 2026 2027 2028 2029 2030
- UTHR fair value vs current price
- UTHR insider transactions and insider buying
- Is UTHR undervalued or overvalued?
- United Therapeutics Corporation financial analysis — revenue, earnings, cash flow
- UTHR Piotroski F-Score and Altman Z-Score
- UTHR analyst price target and Smart Rating
United Therapeutics Corporation
📊 No data available
Try selecting a different time range
UTHR Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · United Therapeutics Corporation (UTHR)
UTHR trades at a significant discount to its Graham intrinsic value of $1282.02, offering a 63% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
United Therapeutics Corporation (UTHR) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, eps growth. Overall metrics suggest strong investment potential with favorable risk/reward.
United Therapeutics Corporation (UTHR) Key Strengths (6)
Keeps $45 of every $100 in revenue after operating costs
Keeps $42 of every $100 in revenue as net profit
98.09% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong earnings growth at 24.50% per year
Solid profitability: $20 profit per $100 equity
Supporting Valuation Data
United Therapeutics Corporation (UTHR) Areas to Watch (4)
Paying a premium for growth, expensive relative to earnings expansion
Premium valuation at 7.5x annual revenue
Premium pricing at 3.2x book value
Modest revenue growth at 7.40%
Supporting Valuation Data
United Therapeutics Corporation (UTHR) Detailed Analysis Report
Overall Assessment
This company scores 67/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Profit Margin, Institutional Own.. Profitability is solid with Return on Equity at 19.70%, Operating Margin at 45.00%, Profit Margin at 41.90%. Growth metrics are encouraging with EPS Growth at 24.50%.
The Bear Case
The primary concerns are PEG Ratio, Price/Sales, Price/Book. Some valuation metrics including PEG Ratio (2.17), Price/Sales (7.46), Price/Book (3.24) suggest expensive pricing. Growth concerns include Revenue Growth at 7.40%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 19.70% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 7.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Operating Margin, Profit Margin) and negatives (PEG Ratio, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
UTHR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
UTHR's Price-to-Sales ratio of 7.46x sits near its historical average of 7.96x (72th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 72% below its historical high of 26.99x set in Nov 2007, and 196% above its historical low of 2.52x in Jan 2013.
Compare UTHR with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for United Therapeutics Corporation (UTHR) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
United Therapeutics Corporation is a mature, profitable business with steady cash generation. Revenue reached 3.2B with 7% growth year-over-year. Profit margins are strong at 41.9%, reflecting pricing power and operational efficiency.
Key Findings
Profit margin of 41.9% and operating margin of 45.0% demonstrate strong pricing power and operational efficiency.
Generating 173M in free cash flow and 346M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact United Therapeutics Corporation.
Bottom Line
United Therapeutics Corporation is a well-established business delivering consistent profitability with 41.9% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About United Therapeutics Corporation(UTHR)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.